GWM Advisors LLC increased its stake in Zoetis Inc (NYSE:ZTS) by 4.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,776 shares of the company’s stock after buying an additional 295 shares during the quarter. GWM Advisors LLC’s holdings in Zoetis were worth $769,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. FMR LLC lifted its position in Zoetis by 12.2% in the first quarter. FMR LLC now owns 8,127,931 shares of the company’s stock worth $818,239,000 after buying an additional 882,183 shares during the last quarter. BlackRock Inc. lifted its position in Zoetis by 2.2% in the first quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock worth $3,773,759,000 after buying an additional 795,558 shares during the last quarter. Geode Capital Management LLC lifted its position in Zoetis by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock worth $531,801,000 after buying an additional 785,088 shares during the last quarter. American Century Companies Inc. lifted its position in Zoetis by 12.8% in the first quarter. American Century Companies Inc. now owns 4,539,546 shares of the company’s stock worth $456,996,000 after buying an additional 513,924 shares during the last quarter. Finally, Close Asset Management Ltd bought a new stake in Zoetis in the first quarter worth $47,140,000. Institutional investors own 90.42% of the company’s stock.

ZTS has been the subject of a number of analyst reports. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. Craig Hallum raised their price target on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Gabelli downgraded Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Stifel Nicolaus raised their price target on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Finally, Barclays raised their price target on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $115.13.

NYSE:ZTS opened at $127.59 on Thursday. Zoetis Inc has a twelve month low of $78.90 and a twelve month high of $128.41. The company has a market cap of $60.93 billion, a price-to-earnings ratio of 40.76, a price-to-earnings-growth ratio of 3.20 and a beta of 0.92. The stock has a fifty day simple moving average of $117.83 and a 200-day simple moving average of $105.05. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same period last year, the company earned $0.77 earnings per share. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, equities research analysts predict that Zoetis Inc will post 3.57 EPS for the current fiscal year.

In other news, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the transaction, the executive vice president now owns 33,190 shares in the company, valued at $4,181,608.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Willie M. Reed sold 1,900 shares of the firm’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total value of $210,102.00. Following the transaction, the director now owns 2,816 shares in the company, valued at approximately $311,393.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,432 shares of company stock valued at $5,083,246. Corporate insiders own 0.29% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What Are Treasury Bonds?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.